ABOUT US R&D FIDELTA INVESTORS NEWS & EVENTS CAREERS CONTACT September 25, 2015 Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis Online Half-year Report 2015 Galapagos is a clinical stage biotech company focused on developing novel mode of action medicines. Headquartered in Belgium, the Company employs 400 people. Galapagos’ most advanced candidate drug filgotinib shows excellent safety and efficacy in rheumatoid arthritis patients and is fully proprietary to Galapagos. With filgotinib, Galapagos demonstrates its capabilities in developing novel medicines for difficult to cure diseases. Click here for the oral presentation on Phase 1 results with GLPG1690 at ERS 2015 Click here for the poster on Phase 1 results with GLPG1690 at ERS 2015 Click here for the poster on pre-clinical data with GLPG1690 at ERS 2015 Call +1(719) 457-0820, code 304536280 to replay the conference call on Sept. 25, 2015 Click here for the DARWIN 2 study 24 week final results webcast Click here for the DARWIN 2 study 24 week final results transcript Click here for the DARWIN 2 study 24 week final results presentation Click here for the DARWIN 1 study 24 week final results webcast Click here for the DARWIN 1 study 24 week final results presentation Click here for the DARWIN 1 study 24 week final results transcript Click here to play back the DARWIN 2 study 12 week results webcast Click here for the DARWIN 2 study 12 week results webcast slide deck Click here for the DARWIN 2 study 12 week results webcast transcript Click here to play back the DARWIN 1 study 12 week results webcast Click here for the DARWIN 1 study 12 week results webcast slide deck Click here for the DARWIN 1 study 12 week results webcast transcript © Copyright 2015 Galapagos NV | Disclaimer | General Purchase Terms Test